Trends to watch
The end of the $1,000 pill? President-elect Donald Trump has signaled that he will keep a close eye on the cost of drugs, highlighted in recent years by Foster City-based Gilead Sciences Inc.’s $1,000-a-pill hepatitis C drugs. Trump hasn’t said exactly how his administration would lower those costs, but the art of the deal may come in loosening regulations that would make it easier for drugs to be approved, letting the free market (not the FDA) decide which ones are effective.
The…
Trends to watch
The end of the $1,000 pill? President-elect Donald Trump has signaled that he will keep a close eye on the cost of drugs, highlighted in recent years by Foster City-based Gilead Sciences Inc.’s $1,000-a-pill hepatitis C drugs. Trump hasn’t said exactly how his administration would lower those costs, but the art of the deal may come in loosening regulations that would make it easier for drugs to be approved, letting the free market (not the FDA) decide which ones are effective.
The…